Discovery Licensing
BivectorAI's geometric screening platform has identified drug and material candidates included in BivectorAI U.S. Provisional Application E (No. 64/150,473, filed September 8, 2026). The candidate records are included within the bounded composition-of-matter scope of Application E. All candidates below are computational research outputs. No compound has undergone wet-lab synthesis, experimental validation, or clinical testing. Use in drug or material development requires independent experimental validation, regulatory approval, and compliance with applicable law.
This is not a self-service product. Access requires an NDA and a direct engagement — Commercial terms are discussed privately and confirmed by written agreement.
Two computational candidate portfolios. One direct licensing path.
Review the currently published candidate sets, their explicit computational evidence boundary and the commercial structure for direct evaluation under NDA. This page is a licensing catalog, not a self-service discovery engine.
325 filed candidate records · 323 unique molecular species · 52 target series · 17 registry disease-area labels.
439 unique computational material candidates · 197 P1 + 242 P2 · 200 with Materials Project negative-search evidence.
325 candidates across 52 target series
118 distinct structural scaffold clusters. 323 unique exact molecular species. Screened computationally across target-engagement, selectivity, safety-signal and synthetic-accessibility evidence dimensions.
Therapeutic areas represented in the filed candidate set
Application E contains 325 drug-candidate records across 52 target series and 17 registry disease-area labels. The portfolio is presented publicly by therapeutic relevance so pharmaceutical and biotechnology teams can identify applicable programs without exposing candidate structures.
Oncology & cancer research
Candidate series relevant to targeted oncology, kinase signaling, mutant oncogenes and DNA-damage-response programs.
Filed target coverage includes MET, ABL, ALK, BRAF, HER2, CDK2, CDK4, CDK6, ATR, PARP1, BTK, FLT3, IDH1, IDH2, JAK2, KRAS G12C, KRAS G12D, AKT1, mTOR, PI3Kα, FGFR1, RET and VEGFR2.
Cardiovascular, coagulation & lipid research
Candidate series relevant to cardiovascular, coagulation, thrombosis and lipid-pathway programs.
Filed target coverage includes ACE, Factor Xa, HMG-CoA reductase, PCSK9 and Thrombin.
CNS & neurodegeneration research
Candidate series relevant to neurological and neurodegeneration drug-discovery programs.
Filed target coverage includes AChE, GSK3β, MAO-B and BACE1.
Infectious-disease research
Candidate series span viral, parasitic and bacterial target programs.
Filed target coverage includes SARS-CoV-2 Mpro and PLpro, HIV integrase, HIV protease, HIV reverse transcriptase, PfDHFR, PfDHOD, InhA and TB-INHA-R.
Inflammation & immune-pathway research
Candidate series relevant to inflammatory and immune-signaling drug-discovery programs.
Filed target coverage includes COX-2, JAK1, PDE4B and TACE/ADAM17.
Metabolic & diabetes-related research
Candidate series relevant to metabolic and diabetes-related drug-discovery programs.
Filed target coverage includes aldose reductase, DPP-4 and PPARγ.
Cardiac function & rhythm research
Candidate series relevant to cardiac signaling, calcium handling and rhythm-focused research.
Filed target coverage includes CaMKII, PKCα and RyR2.
Antifungal research
A dedicated fungal target program is represented in the filed candidate registry.
Filed target coverage includes CYP51.
How far the drug candidates have progressed
These are candidate-level computational records, not merely target ideas. Application E reproduces exact molecular identities and associated screening evidence, while physical and clinical validation remain future gates.
All 325 source records have complete molecular identity in Application E. Exact structures remain off the public website.
Filed records include target screening, computational safety and drug-likeness, synthetic-accessibility and docking-related evidence.
The September 1, 2026 search recorded 255 source records with no PubChem match and 70 with PubChem matches.
Application E does not represent these candidates as synthesized, experimentally validated, clinically validated or approved.
MET, IDH1+PCSK9+PDE4B, BRAF+INHA+TBINHAR
439 computational exact-formula candidates
The 439 computational material candidates are maintained with supporting and negative-evidence records for bounded evaluation. Detailed prioritization methodology and source-specific screening records are reserved for qualified review under NDA.
Material application areas represented in Application E
Application E contains 439 unique computational material-candidate formulas: 197 P1 and 242 P2. The filing also contains structural and application support across 17 material template families. Exact candidate formulas are not published here.
Batteries & solid electrolytes
Filed family support includes solid-electrolyte, sodium electrochemical and battery-coating contexts.
Relevant to battery manufacturers, solid-state battery developers and advanced energy-storage R&D.
Semiconductors & 2D materials
Filed support includes nitride, 2D semiconductor and thin-film material families.
Relevant to semiconductor, electronics and advanced-device R&D.
Memristive & electronic materials
Application E includes memristive-oxide structural and application support.
Relevant to advanced memory, switching and electronic-material research.
Porous materials & MOFs
Filed framework support includes gas capture, storage, separation and water-interaction applications.
Relevant to carbon-management, industrial-gas and separation technology.
Catalysis
Application E includes nitrogen-fixation and CO₂-reduction catalyst family support.
Relevant to chemical manufacturing, carbon conversion and catalytic-process R&D.
Superconducting materials
Nickelate-superconductor material families are represented in the filed application.
Relevant to superconductivity and condensed-matter research.
Thermoelectric materials
Filed support includes skutterudite and Half-Heusler material families.
Relevant to thermal-energy conversion and waste-heat recovery.
Magnetocaloric materials
Magnetocaloric structural/application support is reproduced in Application E.
Relevant to advanced thermal-management and solid-state cooling research.
Piezoelectric materials
Piezoelectric material families are represented in the filed structural support.
Relevant to sensing, actuation, transduction and energy harvesting.
High-entropy structural alloys
Application E includes high-entropy structural-alloy family support.
Relevant to advanced structural and high-performance engineering materials.
Ultra-high-temperature ceramics
Ultra-high-temperature ceramic families are represented in Application E.
Relevant to extreme-temperature and aerospace-material research.
Antimicrobial coatings
Antimicrobial-coating material families are included in the filed support.
Relevant to functional coatings, surfaces and antimicrobial-material research.
How far the material candidates have progressed
The filed portfolio has progressed to exact formula-level candidate identity, P1/P2 prioritization and database-search evidence. Experimental material properties remain a future validation gate.
Application E reproduces all 439 computational candidate formulas. Exact formulas remain off the public website.
Every candidate in the current 439-record set carries a P1 or P2 priority classification.
19 records were element-system negative and 181 additional P1 records were exact-formula negative, producing 200 database-negative records.
Experimental synthesis, phase confirmation, property measurement and application qualification are not represented as completed.
Pricing above covers only the drug and material candidate compositions included in U.S. Provisional Application E (No. 64/150,473). It does not include additional candidate sets that are not included in that filed application.